1. Home
  2. LCNB vs ELTX Comparison

LCNB vs ELTX Comparison

Compare LCNB & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LCNB Corporation

LCNB

LCNB Corporation

HOLD

Current Price

$17.79

Market Cap

223.1M

Sector

Finance

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$3.26

Market Cap

185.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCNB
ELTX
Founded
1877
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.1M
185.4M
IPO Year
1999
2014

Fundamental Metrics

Financial Performance
Metric
LCNB
ELTX
Price
$17.79
$3.26
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$18.00
AVG Volume (30 Days)
36.1K
4.5M
Earning Date
04-22-2026
05-12-2026
Dividend Yield
5.43%
N/A
EPS Growth
68.04
39.29
EPS
0.31
N/A
Revenue
$6,445,000.00
$2,301,000.00
Revenue This Year
$8.50
N/A
Revenue Next Year
$3.66
N/A
P/E Ratio
$56.87
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.11
$2.66
52 Week High
$18.52
$16.00

Technical Indicators

Market Signals
Indicator
LCNB
ELTX
Relative Strength Index (RSI) 56.56 36.07
Support Level $15.28 $2.66
Resistance Level $18.52 $9.76
Average True Range (ATR) 0.49 0.50
MACD -0.04 0.11
Stochastic Oscillator 56.46 18.77

Price Performance

Historical Comparison
LCNB
ELTX

About LCNB LCNB Corporation

LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: